May 6, 2008 by Brian Orelli, PhDFree DrugsFree drugs are a win-win for health insurers and their members.
May 6, 2008 by Brian Orelli, PhDA Sign of the Pharma TimesMerck is the latest big pharma cutting jobs to improve its bottom line.
May 5, 2008 by Brian Orelli, PhDA Short Wait for Discovery Labs?The company gets a third letter about Surfaxin, but should be able to satisfy the FDA soon.
May 2, 2008 by Brian Orelli, PhDBABY's Growing and Eating RightNatus Medical sees steady growth from its smart acquisitions.
May 2, 2008 by Brian Orelli, PhDSepracor Diversifies to Sleep BetterWith its two top drugs in decline, diversification was the only answer.
Apr 30, 2008 by Brian Orelli, PhDMedco's Far-From-Generic QuarterThe pharmacy benefit manager benefits from new generic drugs.
Apr 30, 2008 by Brian Orelli, PhDMomenta RestartedThe FDA gives the drugmaker a pathway to approval for a generic.
Apr 29, 2008 by Brian Orelli, PhDMerck's Recovery Flushed DownMerck's best hope at recovery fails approval by the FDA.
Apr 28, 2008 by Brian Orelli, PhDFDA Moves Isis' Finish LineDrugmaker Isis must complete cancer tests before submitting its marketing application.
Apr 25, 2008 by Brian Orelli, PhDAffymetrix Learns About InertiaSlower sales of its older chips drag down growth.
Apr 25, 2008 by Brian Orelli, PhDProgenics' Double Dose of Good NewsIts lead drug gets FDA approval and a positive EU recommendation.
Apr 24, 2008 by Brian Orelli, PhDIs Schering-Plough the Comeback Kid?Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
Apr 23, 2008 by Brian Orelli, PhDBoston Scientific Gets It DoneWho can fault unattractive results when the bottom line increases?
Apr 23, 2008 by Brian Orelli, PhDWyeth Recovers From Its HeartburnWyeth deals with generic competition for one of its biggest drugs.
Apr 22, 2008 by Brian Orelli, PhDAmylin Treads WaterOne-drug wonders can't get away with stagnant growth.
Apr 22, 2008 by Brian Orelli, PhDWill Merck Make It?Merck releases first-quarter results and says it can make its previous guidance.
Apr 18, 2008 by Brian Orelli, PhDIntuitive Surgical on SaleA price drop following an earnings beat? Sounds like a sale to me.
Apr 18, 2008 by Brian Orelli, PhDRecalls Can't Beat BaxterRecalls, schmecalls. This company's ready to grow.
